Fig. 1: TACC3 is highly expressed in PDAC and inversely correlates with patient survival. | Cell Death & Disease

Fig. 1: TACC3 is highly expressed in PDAC and inversely correlates with patient survival.

From: Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer

Fig. 1

A Differential expression of TACC3 between different disease states (Tumor or Normal) in PDAC was analyzed by TCGA and GTEx database. B Representative images of negative TACC3 IHC staining in normal pancreas and representative images of strong positive TACC3 IHC staining in pancreatic ductal adenocarcinoma (PDAC) tissue; Representative images of weakly positive Ki-67 IHC staining in normal pancreas and representative images of strongly positive Ki-67 IHC staining in PDAC tissue. Scale bar: 100 µm. C Western blotting analysis of TACC3 expression levels in three paired PDAC tissues (T) and adjacent normal pancreatic tissue (N). D qPCR analysis of TACC3 mRNA expression levels in three paired PDAC tissues (T) and adjacent normal pancreatic tissue (N). 10 PDAC tissue samples from LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre (KPC) mice and 10 normal pancreatic tissue samples from wild-type (WT) C57BL/6 J mice were collected for H&E staining and IHC staining analysis. E Representative images of H&E staining, Ki-67 IHC staining, TACC3 IHC staining of normal pancreatic tissue, pancreatic intraepithelial neoplasia (PanINs) and PDAC tissue. Scale bar: 50 µm. F Representative images of high/low TACC3 protein expression in PDAC samples from FUSCC-TMA samples. Scale bar: 200 µm. G In PDAC tissue samples from TMA, Kaplan-Meier survival analysis was used to assess the association between high/low expression of TACC3 and clinical outcome. High TACC3 expression was significantly associated with poor prognosis (median: 19.73 months vs. 41.50 months, respectively; log-rank test, P < 0.001). H Clinical samples acquired from TCGA and analyzed by R-4.1.3 showed that high TACC3 expression was associated with poor prognosis in PDAC (median: 485 days vs. 627 days, respectively; log-rank test, P = 0.026). I Western blotting examined the abundance of TACC3 in six established human pancreatic cancer cell lines, using H6C7 human normal pancreatic duct epithelial cells as a control; using GAPDH as a loading control. J qPCR examined the abundance of TACC3 in six established human pancreatic cancer cell lines, using H6C7 human normal pancreatic duct epithelial cells as a control. (All studies were performed with three biological replicates).

Back to article page